Imaginatik plc
                                        ("Imaginatik" or the "Company")

                   Imaginatik to fund expansion with investment of up to �500,000 by Pfizer

21st  February  2008  - Imaginatik plc (AIM:IMTK), a leading provider of innovation and collaborative  problem-
solving  software  and  processes,  is  pleased  to announce today  that  Pfizer  Inc  ("Pfizer"),  the  global
pharmaceutical  company and a customer of Imaginatik, has agreed to subscribe up to �500,000 for  new  ordinary
shares  of  0.0625p each in the Company (the "Subscription Shares") (the "Subscription"). The funding  will  be
used  to  expand Imaginatik's enterprise social networking and collaboration technology to further improve  the
Company's offering in this sector.

Pfizer's R&D division has been using Imaginatik's software since 2005. At this time, in addition to the  equity
investment,  Pfizer Inc. is purchasing 10,000 new licences of Imaginatik's Idea Central software,  to  evaluate
the  use  of the software in other units within the company. This expansion in the user base brings  the  total
number of Imaginatik's Idea Central subscribers within Pfizer to 25,400.

Mark  Turrell,  CEO  of  Imaginatik  plc, commented, "Our customers embrace collaborative  innovation  and  use
Imaginatik's  technology  to tap into the wisdom and insights of their employee base  and  extended  enterprise
partners.  Pfizer's equity investment provides capital for our company at a critical growth phase and  supports
the value of Imaginatik's enterprise social networking software and overall business vision."


Additional Information on the Subscription

Pfizer  has  agreed to subscribe for up to 12,953,368 Subscription Shares. The maximum number  of  Subscription
Shares  to  be  allotted and issued under the Subscription is within the number of ordinary  shares  which  the
directors  of  Imaginatik  have authority to allot and free from statutory rights of pre-emption,  pursuant  to
existing  authorities granted by shareholders of Imaginatik at the last annual general meeting of  the  Company
held on 27 July 2007.

The subscription price for a Subscription Share ("Subscription Price") and number of Subscription Shares to  be
issued  is  based upon a 5% premium to the average closing offer price of an ordinary share in Imaginatik  over
the  five  dealing days following (and including the date of) this announcement (21st  February - 27th February
2008).  The  number  of  Subscription  Shares or the aggregate amount to be  subscribed  by  Pfizer  under  the
Subscription  will be subject to adjustment if the Subscription Price shall be greater than or less  than  3.86
pence per Subscription Share. There is a limit on the maximum Pfizer shareholding such that the final number of
Subscription Shares will not exceed 10% of the Company's enlarged issued share capital following completion  of
the Subscription ("Completion").

Completion  is conditional on admission to trading on AIM of the Subscription Shares occurring on  or  by  13th
March 2008 ("Admission").  Application for Admission will be made following the determination of the number  of
Subscription  Shares to be issued and the Subscription Price, and the Company will make a further  announcement
about  this  at that time. Admission is expected to occur on 6th March 2008.  Each Subscription Share  will  be
issued credited as fully paid and free from all liens, equities, charges, encumbrances and other interests  and
will  upon their issue rank in full for all dividends and distributions thereafter declared, made or paid after
Admission  and  shall  otherwise rank pari passu in all respects with, and carry the same voting  and  dividend
rights as, the existing ordinary shares.


Pfizer  has also agreed not to dispose of its interest in the Subscription Shares for a period of twelve months
following  Admission and for a subsequent period of twelve months not to dispose of such interests  other  than
through  WH  Ireland  Limited or the Company's broker at the time, without in each  case  the  consent  of  the
Company, and save in each case in certain limited circumstances.


For further information please contact:

Imaginatik plc                                                           Tel: +44 (0)20 7917 2975
Mark Turrell, CEO / Shawn Taylor, CFO

WH Ireland                                                               Tel: +44 (0)121 265 6330
Tim Cofman/Katy Birkin

Investor relations and UK media                                          Tel: +44 (0)20 7651 8688
ICIS
Tom Moriarty / Caroline Evans Jones

US media relations                                                       Tel: +1 202-652-2250
Adam Dubitsky

About Imaginatik

Imaginatik is the leading provider of innovation and collaborative problem solving software and process to  the
world's  leading  companies. More than 100 clients rely on Imaginatik's software, consulting  and  research  to
enable their best-of-breed innovation activities.

Named as a World Economic Forum Technology Pioneer for 2008 and a finalist for the IBM Lotus Awards 2008 in the
Best  Industry  Solution category, Imaginatik's software and consulting services have helped  clients  discover
significant sources of additional revenue, as well as tangible cost savings, process improvements and increased
product  pipeline. Imaginatik is also committed to developing strategic solutions in the field  of  innovation,
working  with academic institutions such as the London Business School and the Cass School of Business, London,
as well as leading practitioners of corporate innovation.

For further information please visit http://www.imaginatik.com


                                                                
Imaginatik Plc
Abal (LSE:ABAL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Abal Charts.
Abal (LSE:ABAL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Abal Charts.